United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. cut its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 2.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 191,925 shares of the biotechnology company's stock after selling 4,094 shares during the period. Robeco Institutional Asset Management B.V. owned approximately 0.43% of United Therapeutics worth $67,719,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. USA Financial Formulas purchased a new stake in United Therapeutics in the 3rd quarter worth about $33,000. Brooklyn Investment Group bought a new position in shares of United Therapeutics in the third quarter worth approximately $33,000. Capital Performance Advisors LLP bought a new stake in shares of United Therapeutics in the third quarter worth about $82,000. MassMutual Private Wealth & Trust FSB grew its stake in United Therapeutics by 31.9% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company's stock worth $85,000 after purchasing an additional 58 shares during the period. Finally, Values First Advisors Inc. purchased a new position in United Therapeutics during the 3rd quarter valued at about $90,000. Institutional investors and hedge funds own 94.08% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on UTHR. StockNews.com raised shares of United Therapeutics from a "buy" rating to a "strong-buy" rating in a report on Thursday, January 16th. Argus lifted their target price on United Therapeutics from $360.00 to $400.00 and gave the stock a "buy" rating in a report on Thursday, October 31st. Oppenheimer boosted their price target on shares of United Therapeutics from $575.00 to $600.00 and gave the company an "outperform" rating in a report on Thursday, October 31st. LADENBURG THALM/SH SH lifted their price objective on shares of United Therapeutics from $319.00 to $344.00 and gave the stock a "buy" rating in a research note on Thursday, October 31st. Finally, UBS Group raised their price objective on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a "buy" rating in a research note on Wednesday, January 8th. One analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $378.36.

United Therapeutics Stock Down 5.5 %

UTHR traded down $20.45 during trading on Thursday, reaching $352.30. The company had a trading volume of 500,887 shares, compared to its average volume of 291,003. The business has a 50 day simple moving average of $365.47 and a 200-day simple moving average of $356.78. United Therapeutics Co. has a 52 week low of $208.62 and a 52 week high of $417.82. The stock has a market cap of $15.73 billion, a P/E ratio of 15.47, a PEG ratio of 0.95 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, topping the consensus estimate of $6.16 by $0.23. The firm had revenue of $748.90 million for the quarter, compared to the consensus estimate of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company's revenue for the quarter was up 22.9% on a year-over-year basis. During the same period last year, the firm posted $5.38 earnings per share. As a group, equities research analysts expect that United Therapeutics Co. will post 25.22 EPS for the current fiscal year.

Insider Activity

In other United Therapeutics news, EVP Paul A. Mahon sold 7,700 shares of the business's stock in a transaction dated Thursday, November 21st. The stock was sold at an average price of $367.36, for a total value of $2,828,672.00. Following the transaction, the executive vice president now owns 36,710 shares in the company, valued at $13,485,785.60. The trade was a 17.34 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Judy D. Olian sold 1,750 shares of the stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $412.48, for a total value of $721,840.00. Following the sale, the director now owns 5,655 shares of the company's stock, valued at approximately $2,332,574.40. The trade was a 23.63 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 149,048 shares of company stock valued at $56,142,199. Company insiders own 11.90% of the company's stock.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.